285 related articles for article (PubMed ID: 33619612)
1. Liquid Crystalline Phases for Enhancement of Oral Bioavailability.
Zhang X; Wu W
AAPS PharmSciTech; 2021 Feb; 22(3):81. PubMed ID: 33619612
[TBL] [Abstract][Full Text] [Related]
2. Lyotropic liquid crystalline phases: Drug delivery and biomedical applications.
Chavda VP; Dyawanapelly S; Dawre S; Ferreira-Faria I; Bezbaruah R; Rani Gogoi N; Kolimi P; Dave DJ; Paiva-Santos AC; Vora LK
Int J Pharm; 2023 Nov; 647():123546. PubMed ID: 37884213
[TBL] [Abstract][Full Text] [Related]
3. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.
Boyd BJ; Khoo SM; Whittaker DV; Davey G; Porter CJ
Int J Pharm; 2007 Aug; 340(1-2):52-60. PubMed ID: 17467935
[TBL] [Abstract][Full Text] [Related]
4. Oral and transdermal drug delivery systems: role of lipid-based lyotropic liquid crystals.
Rajabalaya R; Musa MN; Kifli N; David SR
Drug Des Devel Ther; 2017; 11():393-406. PubMed ID: 28243062
[TBL] [Abstract][Full Text] [Related]
5. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation.
Nguyen TH; Hanley T; Porter CJ; Larson I; Boyd BJ
J Pharm Pharmacol; 2010 Jul; 62(7):856-65. PubMed ID: 20636873
[TBL] [Abstract][Full Text] [Related]
6. Hexagonal Liquid Crystalline Nanodispersions Proven Superiority for Enhanced Oral Delivery of Rosuvastatin: In Vitro Characterization and In Vivo Pharmacokinetic Study.
Gabr MM; Mortada SM; Sallam MA
J Pharm Sci; 2017 Oct; 106(10):3103-3112. PubMed ID: 28479357
[TBL] [Abstract][Full Text] [Related]
7. Recent patents on nonlamellar liquid crystalline lipid phases in drug delivery.
Koynova R; Tenchov B
Recent Pat Drug Deliv Formul; 2013 Dec; 7(3):165-73. PubMed ID: 23829393
[TBL] [Abstract][Full Text] [Related]
8. Cubosomes and hexosomes as versatile platforms for drug delivery.
Azmi ID; Moghimi SM; Yaghmur A
Ther Deliv; 2015; 6(12):1347-64. PubMed ID: 26652281
[TBL] [Abstract][Full Text] [Related]
9. The In Vitro Lipolysis of Lipid-Based Drug Delivery Systems: A Newly Identified Relationship between Drug Release and Liquid Crystalline Phase.
Xiao L; Yi T; Liu Y; Zhou H
Biomed Res Int; 2016; 2016():2364317. PubMed ID: 27294110
[TBL] [Abstract][Full Text] [Related]
10. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin.
Liu Y; Wang L; Zhao Y; He M; Zhang X; Niu M; Feng N
Int J Pharm; 2014 Dec; 476(1-2):169-77. PubMed ID: 25280882
[TBL] [Abstract][Full Text] [Related]
11. Liquid crystalline drug delivery vehicles for oral and IV/subcutaneous administration of poorly soluble (and soluble) drugs.
Otte A; Soh BK; Yoon G; Park K
Int J Pharm; 2018 Mar; 539(1-2):175-183. PubMed ID: 29371020
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems.
Heshmati N; Cheng X; Dapat E; Sassene P; Eisenbrand G; Fricker G; Müllertz A
J Pharm Pharmacol; 2014 Nov; 66(11):1567-75. PubMed ID: 24961657
[TBL] [Abstract][Full Text] [Related]
13. Current potential and challenges in the advances of liquid crystalline nanoparticles as drug delivery systems.
Madheswaran T; Kandasamy M; Bose RJ; Karuppagounder V
Drug Discov Today; 2019 Jul; 24(7):1405-1412. PubMed ID: 31102731
[TBL] [Abstract][Full Text] [Related]
14. Nanostructured liquid crystalline particles provide long duration sustained-release effect for a poorly water soluble drug after oral administration.
Nguyen TH; Hanley T; Porter CJ; Boyd BJ
J Control Release; 2011 Jul; 153(2):180-6. PubMed ID: 21497623
[TBL] [Abstract][Full Text] [Related]
15. Examining the gastrointestinal transit of lipid-based liquid crystalline systems using whole-animal imaging.
Pham AC; Nguyen TH; Nowell CJ; Graham B; Boyd BJ
Drug Deliv Transl Res; 2015 Dec; 5(6):566-74. PubMed ID: 26328930
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured cubosomes as advanced drug delivery system.
Pan X; Han K; Peng X; Yang Z; Qin L; Zhu C; Huang X; Shi X; Dian L; Lu M; Wu C
Curr Pharm Des; 2013; 19(35):6290-7. PubMed ID: 23470001
[TBL] [Abstract][Full Text] [Related]
17. Non-Lamellar Lyotropic Liquid Crystalline Lipid Nanoparticles for the Next Generation of Nanomedicine.
Zhai J; Fong C; Tran N; Drummond CJ
ACS Nano; 2019 Jun; 13(6):6178-6206. PubMed ID: 31082192
[TBL] [Abstract][Full Text] [Related]
18. Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.
Shangguan M; Lu Y; Qi J; Han J; Tian Z; Xie Y; Hu F; Yuan H; Wu W
J Biomater Appl; 2014 Feb; 28(6):887-96. PubMed ID: 24008629
[TBL] [Abstract][Full Text] [Related]
19. Improving oral bioavailability of medicinal herbal compounds through lipid-based formulations - A Scoping Review.
Tan OJ; Loo HL; Thiagarajah G; Palanisamy UD; Sundralingam U
Phytomedicine; 2021 Sep; 90():153651. PubMed ID: 34340903
[TBL] [Abstract][Full Text] [Related]
20. Cubic and hexagonal liquid crystals as drug delivery systems.
Chen Y; Ma P; Gui S
Biomed Res Int; 2014; 2014():815981. PubMed ID: 24995330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
